Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression
2020 San Antonio Breast Cancer Symposium
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses study findings that showed mindfulness meditation and survivorship education may effectively reduce depression and related symptoms such as fatigue and sleep disturbance, which pose serious threats to younger women’s health and well-being after being treated for cancer (Abstract GS2-10).
Chirag Shah, MD, of the Cleveland Clinic, discusses the impact of DCISionRT testing on radiation therapy recommendations for patients with ductal carcinoma in situ following lumpectomy. His study found that despite using traditional favorable-risk criteria, radiation recommendations were changed in more than 40% of patients (Abstract PS6-17).
Roisin M. Connolly, MD, of University College Cork, discusses phase III results from the E2112 trial, which showed exemestane plus entinostat did not improve survival in aromatase inhibitor–resistant advanced HR-positive, HER2-negative breast cancer (Abstract GS4-02).
Sibylle Loibl, MD, of the German Breast Group, discusses the first phase III results from the PENELOPE-B study of palbociclib combined with endocrine therapy in patients with hormone receptor–positive, HER2-negative primary breast cancer who are at high risk for relapse after neoadjuvant chemotherapy (Abstract GS1-02).
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with HER2-negative, hormone receptor–positive metastatic breast cancer previously treated with a taxane (Abstract GS4-01).
Editor's note: On March 22, 2021, Odonate Therapeutics announced it was discontinuing the development of tesetaxel and will close the company's operations. Read more here.
Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs chemotherapy in patients with previously treated metastatic triple-negative breast cancer (Abstract GS3-06).